Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Kaufman, Jonathan L  [Clear All Filters]
2023
Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodríguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023.
Nooka AK, Kaufman JL, Rodríguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes T, Holstein SA, Anderson LD, Badros A, et al. A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study. Future Oncol. 2023.
2022
Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodríguez C, et al. Stem cell mobilization yields with daratumumab and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials. Transplant Cell Ther. 2022.
2021
Josepht NS, Gupta VA, Wyman S, Graiser M, Kaufman JL, Almaula D, Andrews J, Hofmeister C, Dhodapkar M, Heffner LT, et al. Benefits of autologous stem cell transplant for elderly myeloma patients in the last quarter of life. Transplant Cell Ther. 2021.
2020
Voorhees PM, Kaufman JL, Laubach JPeter, Sborov DWeston, Reeves B, Rodríguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, et al. Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. Blood. 2020.
2019
Bailur JKini, McCachren SS, Doxie DB, Shrestha M, Pendleton KE, Nooka AK, Neparidze N, Parker TL, Bar N, Kaufman JL, et al. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight. 2019;5.
2018
Mina R, Joseph NS, Kaufman JL, Gupta VA, Heffner LT, Hofmeister CC, Boise LH, Dhodapkar MV, Gleason C, Nooka AK, et al. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer. 2018.